Comparison 3. Topotecan versus PLD.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Hazard Ratio of Survival	1		Hazard Ratio (IV, Fixed, 95% CI)	Subtotals only
3.1.1 Survival	1		Hazard Ratio (IV, Fixed, 95% CI)	1.09 [1.00, 1.19]
3.1.2 Survival(platium‐sensitive)	1		Hazard Ratio (IV, Fixed, 95% CI)	1.17 [1.03, 1.33]
3.1.3 Survival(platium‐resistant)	1		Hazard Ratio (IV, Fixed, 95% CI)	1.03 [0.92, 1.15]
3.2 Survival	1		Other data	No numeric data
3.2.1 Median survival (by week)	1		Other data	No numeric data
3.2.2 median survival‐platium‐sensitive(by week)	1		Other data	No numeric data
3.2.3 median survival‐platium‐resistant(by week)	1		Other data	No numeric data
3.3 Survival	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.3.1 Survival rate at 1‐year follow‐up	1	474	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.81, 1.13]
3.3.2 Survival rate at 2‐year follow‐up	1	474	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.50, 0.90]
3.3.3 Survival rate at 3‐year follow‐up	1	474	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.43, 0.99]
3.3.4 Survival rate at 1‐year follow‐up(platium‐sensitive)	1	219	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.75, 1.06]
3.3.5 Survival rate at 2‐year follow‐up(platium‐sensitive)	1	219	Risk Ratio (M‐H, Fixed, 95% CI)	0.60 [0.43, 0.84]
3.3.6 Survival rate at 3‐year follow‐up(platium‐sensitive)	1	219	Risk Ratio (M‐H, Fixed, 95% CI)	0.61 [0.37, 1.01]
3.3.7 Survival rate at 1‐year follow‐up(platium‐refractory)	1	255	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.78, 1.38]
3.3.8 Survival rate at 2‐year follow‐up(platium‐refractory)	1	255	Risk Ratio (M‐H, Fixed, 95% CI)	0.85 [0.51, 1.41]
3.3.9 Survival rate at 3‐year follow‐up(platium‐refractory)	1	255	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.35, 1.38]
3.4 progression free survival	1		Other data	No numeric data
3.4.1 progression free survival	1		Other data	No numeric data
3.4.2 progression free survival(platium‐sensitive)	1		Other data	No numeric data
3.4.3 progression free survival(platium‐resistant)	1		Other data	No numeric data
3.5 Toxicity	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.1 neutropenia‐overall	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.2 neutropenia‐grade 3/4	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.3 anemia‐overall	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.4 anemia‐grade 3/4	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.5 thrombocytopenia‐overall	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.6 thrombocytopenia‐grade 3/4	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.7 leukopenia‐overall	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.8 leukopenia‐grade 3/4	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.9 alopecia	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.10 PPE	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.5.11 stomatitis	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.6 Symptom control(response)	1	2844	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.71, 1.04]
3.6.1 overall response	1	474	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.59, 1.27]
3.6.2 overall response‐platium sensitive	1	220	Risk Ratio (M‐H, Fixed, 95% CI)	1.01 [0.67, 1.54]
3.6.3 overall response‐platium resistant	1	254	Risk Ratio (M‐H, Fixed, 95% CI)	0.52 [0.23, 1.18]
3.6.4 complete response	1	474	Risk Ratio (M‐H, Fixed, 95% CI)	1.24 [0.52, 2.94]
3.6.5 complete response‐platium sensitive	1	220	Risk Ratio (M‐H, Fixed, 95% CI)	1.23 [0.50, 2.99]
3.6.6 complete response‐platium resistant	1	254	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [0.07, 16.58]
3.6.7 partial response	1	474	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.50, 1.22]
3.6.8 partial response‐platium sensitive	1	220	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.56, 1.58]
3.6.9 partial response‐platium resistant	1	254	Risk Ratio (M‐H, Fixed, 95% CI)	0.49 [0.21, 1.16]